Intravitreales Bevacizumab bei rezidivierender idiopathischer chorioidaler Neovaskularisation

Niemeyer, M.; Hefner, L.; Jochmann, Claudia; Wiedemann, Peter

doi:10.1007/s00347-006-1425-5

Cited by 5 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bevacizumab (Avastin) is another anti-VEGF that has been also successfully used in off-label treatment of neovascular AMD and neovascularization due to pathological myopia [8][9][10][11][12][13][14]. Also, it has shown positive effects on the regression of pathological neovascularization in iris rubeosis [15] and the reduction of macular edema secondary to retinal vein occlusion [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration

Lazić

Gabrić

2006

Graefe's Arch Clin Exp Ophthalmol

113

View full text Add to dashboard Cite

Short-term results suggest that intravitreally administered bevacizumab (Avastin) is effective in minimally classic and occult CNV due to AMD. Significant improvements in VA, CFT and TMV were obtained and maintained during follow-up. In some patients, however, recurrence of leakage requiring additional intravitreal injection occurred. Maintenance of the effect of bevacizumab and its safety after repeated and prolonged administration have to be investigated in well-controlled studies.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Median (range) duration of follow-up was 18(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24) weeks. Statistically significant changes from baseline were observed in best-corrected VA [increase of1.29 lines (P=0.001)], CFT [reduction of 56 μm (P=0.01)], and TMV [reduction of 0.80 mm 3 (P<0.0001)].…”

mentioning

confidence: 99%

Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration

Lazić

Gabrić

2006

Graefe's Arch Clin Exp Ophthalmol

113

View full text Add to dashboard Cite

show abstract

“…One of these new VEGF inhibitors, bevacizumab (Avastin ® ; Roche, Basel, Switzerland), demonstrated a reduced vascular leakage and growth of the CNV (Ladewig et al. 2006; Niemeyer et al. 2007; Spaide et al.…”

Section: Introductionmentioning

confidence: 99%

“…Recently, novel therapeutic agents have been introduced for the treatment of exudative AMD targeting vascular endothelial growth factor (VEGF). One of these new VEGF inhibitors, bevacizumab (Avastin Ò ; Roche, Basel, Switzerland), demonstrated a reduced vascular leakage and growth of the CNV (Ladewig et al 2006;Niemeyer et al 2007;Spaide et al 2006;Yoganathan et al 2006).…”

Section: Introductionmentioning

confidence: 99%

Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study

Meyer

Scholl

Eter

et al. 2008

Acta Ophthalmologica

View full text Add to dashboard Cite

ABSTRACT.Purpose: To assess the effectiveness of consecutive intravitreal injections of recombined tissue plasminogen activator (rtPA), expansile gas and bevacizumab in eyes with acute subretinal haemorrhage (SRH). Methods: A retrospective, non-randomized consecutive case series included 19 eyes in 19 patients with SRH related to exudative age-related macular degeneration (AMD). The initial size of the subfoveal SRH was 1-3 disc diameters. Each patient received a triple procedure using 0.05 ml rtPA (50 lg), 0.3 ml of sulphur hexafluoride (SF6) gas and 0.05 ml bevacizumab (1.25 mg). Lesion size, location of the SRH and early treatment in diabetic retinopathy study (ETDRS) visual acuity were evaluated pretreatment as well as 1 and 3 months after the procedure. Results: At the initial presentation, the patients' mean age was 77 years (range 63-88 years) and the mean duration of symptoms was 9.3 days (range 4-12 days). The mean visual acuity pretreatment (20 ⁄ 133) improved significantly to 20 ⁄ 86 at 1 month and to 20 ⁄ 74 at 3 months. The mean ETDRS visual acuity improved from baseline by 2.1 lines at 1 month (Wilcoxon ranks test; P < 0.005) and 3.7 lines at 3 months after treatment (Wilcoxon ranks test; P < 0.005). None of our patients had reading visual acuity prior to treatment, with visual acuity below 0.3. One month after the triple procedure, 25% of our patients had reading visual acuity ( ‡ 0.4); at 3 months, the figure was 35%. A successful inferior displacement of the SRH was achieved in 17 ⁄ 19 eyes. Eyes with elevated intraocular pressure were treated immediately by a corneal paracentesis. Conclusion: The intravitreal application of rtPA, gas and bevacizumab appears to be beneficial and well tolerated in the treatment of SRH in the short term. The triple approach seems a logical alternative to the current combined dual approach in limiting the progression of the underlying disease and achieving better visual outcome. Further randomized evaluations are warranted.

show abstract

Monitoring von AMD-Patienten unter Anti-VEGF-Therapie

Meyer

Eter

2008

Ophthalmologe

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is one of the most common causes of blindness in western industrialised nations. Most AMD patients suffer from the dry early form of AMD; however, wet AMD with choroidal neovascularization (CNV) is the main cause of blindness in all AMD patients. New prospects have been developed in AMD treatment using pharmacological methods available for treating all subtypes of exudative AMD. A number of inhibiting and inducing growth factors, such as vascular endothelial growth factor (VEGF), are particularly important in the pathophysiology of wet AMD. The secreted VEGF appears to play a crucial role in the pathogenesis of CNV and macular edemas as a result of its angiogenetic and permeability-enhancing effect. This recognition led to the treatment approach now used, i.e., competitive VEGF blocking through intravitreal adminsitration of anti-VEGF drugs. The anti-VEGF durgs lead to a rapid decrease in retinal thickness. Optical coherence tomography (OCT) is a valuable monitoring tool, but may only be used to assist in decision-making. Clinical follow-up of patients and further treatment recommendations must always be guided by the overall clinical picture. Visual acuity is regarded as the decisive criterion for repeat treatment.

show abstract

Intravitreales Bevacizumab bei rezidivierender idiopathischer chorioidaler Neovaskularisation

Cited by 5 publications

References 4 publications

Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration

Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration

Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study

Monitoring von AMD-Patienten unter Anti-VEGF-Therapie

Contact Info

Product

Resources

About